Handelsbanken Fonder AB Has $2.30 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Handelsbanken Fonder AB boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 12,437 shares of the medical research company’s stock after buying an additional 200 shares during the period. Handelsbanken Fonder AB’s holdings in Charles River Laboratories International were worth $2,296,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CRL. Versant Capital Management Inc lifted its holdings in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after buying an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. increased its position in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the period. Assetmark Inc. raised its stake in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares in the last quarter. ORG Wealth Partners LLC bought a new stake in Charles River Laboratories International in the 4th quarter valued at about $56,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Charles River Laboratories International during the 3rd quarter worth approximately $59,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently weighed in on CRL. The Goldman Sachs Group dropped their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Bank of America dropped their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. UBS Group reissued a “neutral” rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. TD Cowen boosted their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $195.71.

Insider Buying and Selling at Charles River Laboratories International

In other news, CEO James C. Foster acquired 6,075 shares of the stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This represents a 3.42 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

CRL stock opened at $170.36 on Tuesday. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $275.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The stock has a market cap of $8.71 billion, a price-to-earnings ratio of 1,135.73, a P/E/G ratio of 4.54 and a beta of 1.37. The company has a 50 day simple moving average of $172.44 and a 200 day simple moving average of $187.78.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same period in the prior year, the business earned $2.46 earnings per share. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. Research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).